Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
Status:
Completed
Trial end date:
2017-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of DFP-10917 given via
continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).